Obstructive Sleep Apnea Syndrome (OSA) is a sleep breathing disorder with high prevalence in the general population and is linked to severe health consequences such as hypertension, daytime sleepiness and cardiovascular disease.
Recent studies suggested a substantial gap in both diagnosis and treatment in Italy, as in many countries, with only 460,000 moderate-severe patients diagnosed (4% of the estimated prevalence) and 230,000 treated (2% of the estimated prevalence). The accepted gold standard for sleep apnea diagnosis is polysomnography (PSG), but access to PSG is often limited, especially in this COVID-19 pandemic period. New home Sleep Apnea Testing (HSAT) has therefore been developed to facilitate the diagnosis of OSAS. OSA severity is still measured by counting respiratory events, while other physiologically relevant consequences are ignored, so more personalized diagnostic approaches are urgently needed by new techniques, such as developing machine learning tools to better estimate obstructive sleep apnea severity and phenotypes.
For OSA treatment, on the basis of the broad spectrum of clinical phenotypes and variety of effective treatment options, we need a “tailored” and multidisciplinary approach which should replace a unidirectional and often low compliance strategy.
This course is tailored for ENT specialists, but it is extremely interesting also for dentists, maxillo-facial and plastic surgeons, pulmonologists and neurologists.
The pearl of the course is to create a face-to-face relationship among the outstanding international faculty and participants, exploring cutting-edge innovations and new technologies in Obstructive Sleep Apnea and Snoring.